{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-030103","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.980722+00:00","generated_at":"2026-06-18T08:32:25.529226+00:00","sec_items":["5.02","5.08","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avenue Therapeutics schedules Type C FDA meeting for IV Tramadol; appoints MacLean to board, Kranzler Chairman","bullets":["Type C FDA meeting on March 9, 2023 to discuss IV Tramadol respiratory depression study protocol; update expected April 2023.","Board expanded to six; CEO Alexandra MacLean appointed director; Jay Kranzler named Chairman, Lindsay Rosenwald remains director.","Annual meeting set for June 22, 2023; record date April 25, 2023; stockholder proposal deadline March 24, 2023.","FDA previously agreed on study design aspects in August 2022 Type A meeting for IV Tramadol."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-030103","json":"https://secwatch.observer/filing/0001104659-23-030103.json","markdown":"https://secwatch.observer/filing/0001104659-23-030103.md","text":"https://secwatch.observer/filing/0001104659-23-030103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/tm238871d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:32:25.529226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68b21b7f34","claim":"Jay Kranzler was appointed as Chairman of the Board at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"aff3c771d5","claim":"Alexandra MacLean was appointed as Director at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}